The Trump Administration Just Defunded the Warning Label on Street Drugs

On the afternoon of July 10, 2025, people started dropping in Baltimore’s Penn North neighborhood — found unresponsive on sidewalks and front steps, some of them not waking up even after paramedics pushed dose after dose of naloxone, the opioid-overdose reversal drug sold as Narcan. By the time it was over, more than two dozen people had been hospitalized. Federal chemists testing the drug samples afterward found something they’d never seen before in Maryland, or anywhere else the government tests street drugs: a synthetic sedative called N-methylclonazepam, chemically related to Xanax and Valium, mixed into fentanyl at roughly ten times the concentration.

It was the first of three mass-overdose events in Penn North within three months. It would not be the last neighborhood in the country to meet this drug for the first time.

Here is the sentence that should follow every retelling of that day: the federal government’s response, a year later, was to make it harder to warn people what they’re about to take.

In late April 2026, the Substance Abuse and Mental Health Services Administration — SAMHSA, the federal agency that funds most of the country’s addiction and overdose-prevention work — sent grantees a Dear Colleague Letter, the memo format the agency uses to tell every organization that takes its money what it can and can’t spend that money on. This one said federal grants can no longer pay for handing out drug-checking test strips — the small paper strips that let someone dip a sample of their own drugs and find out, in about two minutes, whether fentanyl, xylazine, or a benzodiazepine is in it. The letter also cut off funding for clean syringes, safer-smoking supplies, and overdose hotlines, describing those practices as ones that “facilitate illicit drug use and are incompatible with Federal laws,” according to NPR and KFF Health News, who first reported the letter’s effect on Baltimore in early August.

A Drug That Doesn’t Answer to Narcan

If you’ve spent any time around opioid overdose response, you know the choreography by now: someone goes down, someone else administers naloxone, and — usually, if it’s fentanyl or heroin alone — the person comes back. That’s because naloxone works by knocking opioid molecules off the brain’s opioid receptors. It has no effect on benzodiazepines, a completely different class of sedative drug that slows breathing through a different mechanism entirely. Give someone naloxone for a benzodiazepine overdose and, medically, nothing happens — the drug you administered simply isn’t the drug in their system.

That’s what made Penn North frightening in a specific, mechanical way. Edward Sisco, the National Institute of Standards and Technology chemist whose lab identified the compound, said N-methylclonazepam’s “highly sedative effects are consistent with the experiences of those who experienced an overdose in Penn North on 7/10.” At University of Maryland Medical Center, where 14 of the cases were treated, Dr. Cheyenne Falat described emergency physicians working partly on instinct when the usual antidote didn’t fully work: “Some of it is guesswork, but guided by many years of seeing symptoms.” Dr. Enrique Oviedo, who runs a Baltimore addiction clinic, put the supply problem plainly: “We’re talking about very potent, very sedating drugs, and it’s probably being mixed haphazardly.” A second cluster hit the same three-block radius that October — the third mass-overdose event in the neighborhood in three months, as WYPR reported — and Maryland state delegate Jesse Pippy told the outlet he was “really hoping in the next legislative session that we take affirmative action to address it.”

The FDA’s own boxed warning on benzodiazepines — the strongest label the agency puts on a prescription drug — spells out exactly why this combination is so dangerous: benzodiazepines carry “serious risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions,” and those harms compound sharply “when people use benzodiazepines in combination with other drugs,” including opioids. Put simply: mixing a benzodiazepine into fentanyl doesn’t just add a second drug, it adds a second way to stop breathing — one your rescue kit isn’t built to fix.

Baltimore Paid for Its Own Early-Warning System

There was, until this spring, a version of an answer. Test strips have existed for roughly a decade as a way to let people using drugs check for adulterants before they use — not a treatment, not a cure, just information, the same instinct behind a diabetic checking blood sugar or a home radon kit. After the Penn North clusters, the Baltimore Harm Reduction Coalition designed and paid for its own benzodiazepine-specific test strips, distributing them alongside strips that detect fentanyl, xylazine, and medetomidine — two veterinary sedatives that have been showing up more often in the street opioid supply — at clinics and neighborhood outreach events across the city.

Candy Kerr, the coalition’s spokesperson, described the basic problem the strips solve in one line: “Nobody really knows what they’re getting whenever they’re getting stuff off the street.” That is not a throwaway observation — it is the entire argument for harm reduction in nine words. You cannot make an informed decision about a substance whose contents are, by definition, unknown to you, and for years, a test strip was the closest thing to a label that existed. Kerr connected the coalition’s ability to do that work directly to federal money: “We’ve been making these strides forward because we’ve had these things, because we’ve been funded.” When Tom Coderre, who led SAMHSA on an interim basis under the Biden administration, championed test strip funding back in 2021, he said the strips would “save lives by providing tools to identify the growing presence of fentanyl in the nation’s illicit drug supply.” Five years and one new sedative later, the same logic applies to N-methylclonazepam — the government just no longer agrees.

Then Washington Told Baltimore to Stop

SAMHSA’s April letter, signed by acting administrator Chris Carroll, doesn’t ban test strips outright — nonprofits are still legally free to hand them out. What it does is pull the specific federal dollars that paid for buying and distributing them, along with the staff time, outreach vans, and neighborhood events that got them into people’s hands. Under the new guidance, federal money can still fund test strips when used by law enforcement, EMTs, public health officials, and medical professionals — the people testing drugs after the fact, for a report or a case file. It just can’t fund giving a strip directly to the person about to use the drug, which is the only moment a test strip actually prevents an overdose rather than documenting one.

SAMHSA’s April letter, signed by acting administrator Chris Carroll, doesn’t ban test strips outright — nonprofits are still legally free to hand them out.

HHS spokesperson Emily Hilliard defended the policy to NPR and KFF Health News in stark terms: “It is critical that federal funding provided by the American taxpayer goes to effective, common-sense solutions.” Yngvild Olsen, who ran SAMHSA’s Center for Substance Abuse Treatment before this administration, offered a rebuttal grounded in what test strips actually do to behavior — she’s watched people use the information to change what they do next: “There’s some people deciding not to use the substances, some people deciding to reduce, to use less.” Stephen Taylor, president of the American Society of Addiction Medicine, was more measured but no less pointed, saying his organization is “prepared to engage with federal partners to ensure that national policies reflect evidence-based practices in addiction medicine” — the polite version of saying the guidance isn’t one. For the Baltimore Harm Reduction Coalition specifically, the letter means finding other money for the benzodiazepine strips it invented in response to Penn North, while cutting back elsewhere — hygiene kits, wound care supplies — to cover the gap.

We’ve Run This Exact Experiment Before

None of this is a new argument in American drug policy — it is a rerun. In 1988, at the height of the AIDS epidemic among people who injected drugs, Senator Jesse Helms pushed through a provision, codified at 42 U.S.C. § 300ee-5, barring federal money from paying for the syringes handed out at needle exchanges — even though public health researchers already suspected clean syringes slowed the spread of HIV. The ban held for 21 years. By the time Congress finally lifted it in 2009, the CDC and the Institute of Medicine had spent more than a decade documenting what the delay cost: infections that clean-needle access would have prevented, syringe programs forced to run on private donations and volunteer labor while the federal government that funded nearly everything else in public health sat the fight out. Congress reinstated a version of the ban within three years, over the objections of its own public health agencies.

That history matters here because it is not a metaphor — it is the same mechanism, aimed at a different piece of equipment. A federal agency decided that giving people the tools to protect themselves while they use drugs was tantamount to endorsing the use itself, and let that political discomfort override its own health data. Read the SAMHSA harm-reduction guidance next to the 1988 statute and the family resemblance is exact, down to the language of incompatibility with federal law standing in for an actual clinical objection.

Who This Protects, and Who It Doesn’t

Here’s the part that should bother you even if you’ve never touched an illicit drug in your life: this policy doesn’t reduce how many test strips exist in Baltimore. It just decides who has to pay for them. Under the new guidance, a police department can still use federal money to test a sample for a case file — after the fact, for evidence. A person deciding whether to use what’s in their pocket right now cannot get that same information paid for with the same federal dollars. The government has effectively decided that drug-checking is a legitimate public function only once it’s too late to change anyone’s next ten minutes.

If you’re the one holding a baggie tonight, genuinely unsure what’s actually in it, the strip you’d use to check isn’t illegal, and it isn’t gone — it’s just no longer something SAMHSA will pay for. That distinction is exactly the point. This is not a story about test strips disappearing; it’s a story about who absorbs the cost of finding out what’s cut into your drugs, shifted quietly from the federal government back onto the harm reduction nonprofits scraping together private donations, the way Baltimore’s coalition is scraping together money right now for the benzodiazepine strips it built specifically because of what happened on Penn North.

What’s Still Yours Tonight

The bad news is real, and it’s worth sitting with rather than softening. But two things haven’t changed. Naloxone itself remains fully federally funded and legal to carry, distribute, and use — it is still the right first move for any suspected opioid overdose, even one that also involves a depressant like N-methylclonazepam, because it will still reverse whatever fentanyl is in the mix even if it can’t touch the benzodiazepine. And organizations like the Baltimore Harm Reduction Coalition are still handing out fentanyl, xylazine, medetomidine, and benzodiazepine test strips right now, today, funded out of pocket instead of by Washington. The infrastructure didn’t vanish. It just got more expensive to keep standing, which is a fight private donors and state health departments can still choose to win — this piece connects to the same defunding pattern we covered in SAMHSA’s Medicaid cuts to the recovery safety net, and neither fight is over.

The bad news is real, and it’s worth sitting with rather than softening.

What Penn North proved, three times in three months, is that the drug supply moves faster than any bureaucracy tracking it — a new sedative can show up in a Tuesday-afternoon bag before anyone in a position to fund a countermeasure has heard its name. A test strip is one of the only tools that moves at the same speed as the street, cheap enough for a neighborhood coalition to invent one in response to a crisis within weeks. Pulling federal money from that tool doesn’t slow drug use. It just guarantees that the next Penn North finds out what’s in the batch the same way the last one did — in an emergency room, one overdose at a time, with a drug that doesn’t answer to the antidote in anyone’s pocket.